Evidence map›Paper›PMID 35367784›Full record

SynthesisCancer treatment reviews2022

Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.

Amanda J Kerr, David Dodwell, Paul McGale, Francesca Holt, Fran Duane, Gurdeep Mannu, Sarah C Darby, Carolyn W Taylor

2 registry-linked trialsOpen access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer treatment reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 172 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed, 9 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06429189 naunknown statusnot on this mapstarted 2024, after this paper: background citation

An Online Home-based Combined Exercise Intervention With Self-selected Intensity for Women With Breast Cancer: The Home-Combo Randomized Controlled Trial.

TypeinterventionalSponsorGrupo LusófonaRan2024 to 2025Enrolled98ConditionsBreast Cancer, Chemotherapy EffectArmsHome-based combined exercise program with self-selected intensity
NCT07521397 completednot on this map

Pooled Analysis of Individual Patient Data of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy (Ddsc): a Hellenic Cooperative Oncology Group (HeCOG) Study

TypeobservationalSponsorHellenic Cooperative Oncology GroupRan1996 to 2022Enrolled5,358ConditionsBreast Cancer, Early Stage Breast Cancer, Adjuvant Chemotherapy, Prognosis Breast Cancer
3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 9 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Implantable Ports vs Peripherally Inserted Central Catheters in Breast Cancer Chemotherapy: A Comprehensive Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Confounding by indication in the evaluation of neoadjuvant chemotherapy: a sequential Cox analysis of an eight-year single-centre breast cancer cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Strategies for Targeting Mitochondria in the Treatment of Breast Cancer.ACS pharmacology & translational science · 2026
    Review

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Amanda J KerrNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: amanda.kerr@ndph.ox.ac.uk.
David DodwellNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: david.dodwell@ndph.ox.ac.uk.
Paul McGaleNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: paul.mcgale@ndph.ox.ac.uk.
Francesca HoltNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: francesca.holt@ndph.ox.ac.uk.
Fran DuaneSt Luke's Radiation Oncology Network, St. James's Hospital, Dublin, Ireland. Electronic address: fduane@tcd.ie.
Gurdeep MannuNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: gurdeep.mannu@ndph.ox.ac.uk.
Sarah C DarbyNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: sarah.darby@ndph.ox.ac.uk.
Carolyn W TaylorNuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: carolyn.taylor@ndph.ox.ac.uk.
University of Oxford · GBSt. James's Hospital · IE

Funding

Cancer Research UK A21133
6 · The paper itself

Abstract

backgroundAdjuvant and neoadjuvant breast cancer treatments can reduce breast cancer mortality but may increase mortality from other causes. Information regarding treatment benefits and risks is scattered widely through the literature. To inform clinical practice we collated and reviewed the highest quality evidence.

methodsGuidelines were searched to identify adjuvant or neoadjuvant treatment options recommended in early invasive breast cancer. For each option, systematic literature searches identified the highest-ranking evidence. For radiotherapy risks, searches for dose-response relationships and modern organ doses were also undertaken.

resultsTreatment options recommended in the USA and elsewhere included chemotherapy (anthracycline, taxane, platinum, capecitabine), anti-human epidermal growth factor 2 therapy (trastuzumab, pertuzumab, trastuzumab emtansine, neratinib), endocrine therapy (tamoxifen, aromatase inhibitor, ovarian ablation/suppression) and bisphosphonates. Radiotherapy options were after breast conserving surgery (whole breast, partial breast, tumour bed boost, regional nodes) and after mastectomy (chest wall, regional nodes). Treatment options were supported by randomised evidence, including > 10,000 women for eight treatment comparisons, 1,000-10,000 for fifteen and < 1,000 for one. Most treatment comparisons reduced breast cancer mortality or recurrence by 10-25%, with no increase in non-breast-cancer death. Anthracycline chemotherapy and radiotherapy increased overall non-breast-cancer mortality. Anthracycline risk was from heart disease and leukaemia. Radiation-risks were mainly from heart disease, lung cancer and oesophageal cancer, and increased with increasing heart, lung and oesophagus radiation doses respectively. Taxanes increased leukaemia risk.

conclusionsThese benefits and risks inform treatment decisions for individuals and recommendations for groups of women.

Indexed as

Breast NeoplasmsChemotherapy, AdjuvantFemaleHumansMastectomyNeoadjuvant TherapyTamoxifenTamoxifenAdjuvant treatmentsBreast cancerNeoadjuvant treatmentsTreatment benefitsTreatment harms

Identifiers

PMID35367784
PMCPMC9096622
OpenAlexW4214901572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.